69675-08-7

Basic information

• Product Name: 1-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine
• Synonyms: pyridine, 1,2,3,6-tetrahydro-1-methyl-4-(4-methylphenyl)-
• CAS NO: 69675-08-7
• Molecular Formula: C₁₃H₁₇N
• Molecular Weight: 187.2808
• Mol File: 69675-08-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 287°C at 760 mmHg
• Flash Point: 116.3°C
• Density: 0.989g/cm³
• Vapor Pressure: 0.00256mmHg at 25°C
• Refractive Index: 1.549
• CAS DataBase Reference: 1-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine(69675-08-7)
• EPA Substance Registry System: 1-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine(69675-08-7)

Safety Data

• Hazardous Substances Data: 69675-08-7(Hazardous Substances Data)

Usage

Initial purpose

Potential antihypertensive drug
Developed to treat high blood pressure

Notoriety

Neurotoxic effects
Known for its ability to induce symptoms similar to Parkinson's disease

Affects species

Humans and non-human primates
Both species experience similar neurotoxic effects

Metabolism

Converted to MPP+ (a toxic compound)
MPTP is metabolized in the body, leading to the formation of MPP+

Target

Dopamine-producing neurons
MPP+ selectively damages neurons in the substantia nigra region of the brain

Consequence

Irreversible degeneration of dopamine system
Damage to the neurons leads to the degeneration of the dopamine system

Symptoms

Parkinson's disease motor symptoms
Includes tremors, rigidity, and bradykinesia

Scientific significance

Development of animal models for Parkinson's disease
Discovery of MPTP's neurotoxicity has been instrumental in creating models for studying the disease

Contribution

Understanding the underlying mechanisms of Parkinson's disease
MPTP's effects have helped researchers gain insight into the disease's mechanisms

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 454482-11-2 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl )-1,2,3,6-tetrahydropyridine 
• 108-88-3 toluene 
• 4294-57-9 para-methylphenylmagnesium bromide 
• 2417-95-0 p-tolyllithium 
• 100617-72-9 3,6-dimethyl-6-p-tolyl-tetrahydro-[1,3]oxazine 
• 1195-32-0 1-methyl-4-isopropenylbenzene 

Downstream Products

• 4423-10-3 4-(p-tolyl)pyridine 
• 1100765-99-8 1-ethoxycarbonylmethyl-1-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridinium chloride 

Relevant articles and documents

Preparation method of para-substituted aryl compound

The invention discloses a preparation method of a para-substituted aryl compound shown as a formula (I) which is described in the specfication. The preparation method is characterized by comprising the following step of: subjecting an aryl sulfonium salt shown as a formula (II) which is described in the specfication and boride to a coupling reaction in a solvent in an inert atmosphere under the action of alkali and a palladium catalyst to obtain the para-substituted aryl compound. According to the method, mono-substituted aromatic hydrocarbon is taken as a substrate, the aryl sulfonium salt isconstructed in situ, and the palladium catalyst catalyzes the aryl sulfonium salt constructed in situ to undergo the Suzuki-Miyaura coupling reaction, so a mono-substituted aromatic hydrocarbon para-arylation or alkenylation product is constructed quickly and efficiently. The method is mild in conditions, high in substrate universality and wide in tolerance of a heterocyclic coupling substrate.

Assessment of structural requirements for the monoamine oxidase-B- catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine

The monoamine oxidase B (MAO-B) substrate properties and distance measurements along the N1-C4 axis of 38 1,4-disubstituted-1,2,3,6- tetrahydropyridine derivatives, including seven newly synthesized MPTP analogs, were used to define